GBX1 Inhibitors
Chemical inhibitors of GBX1 can modulate its activity through various signaling pathways by targeting specific kinases and enzymes that are upstream or part of the pathways that regulate GBX1 function. U0126 and PD98059 are both inhibitors of MEK, a kinase that is crucial for the activation of the ERK pathway, a signaling cascade that can govern the activity of GBX1. The inhibition of MEK by these compounds prevents the phosphorylation and subsequent activation of ERK, leading to the reduction in GBX1 activity that is dependent on this pathway. Similarly, LY294002 and Wortmannin are both inhibitors of PI3K, leading to a decrease in Akt phosphorylation and activity, which in turn can inhibit GBX1. Rapamycin directly inhibits mTOR, a central component of the PI3K/Akt pathway, and its inhibition can also disrupt signals that are necessary for the proper functioning of GBX1.
Further, SB203580 and SP600125 target different members of the MAPK family, namely p38 MAP kinase and JNK, respectively. These kinases are integral to distinct signaling pathways that can influence GBX1 activity. By inhibiting these kinases, SB203580 and SP600125 can decrease the functional activity of GBX1. PP2, a selective inhibitor of Src family kinases, can indirectly reduce GBX1 activity by altering upstream regulatory signals. SB431542 disrupts the TGF-β signaling pathway by inhibiting the TGF-β receptor type I, which can also impact the activity of GBX1. Y-27632 targets the ROCK kinase that affects actin cytoskeleton dynamics, potentially leading to cellular structural changes that can reduce GBX1 activity. PD173074, which selectively inhibits FGFR, can alter the signaling that interacts with GBX1 regulatory pathways, leading to its inhibition. Lastly, DAPT inhibits gamma-secretase, an enzyme complex involved in the Notch signaling pathway, which can also affect GBX1 by altering the signaling milieu in which it operates. Each of these inhibitors can affect GBX1 by interfering with the specific signaling pathways that are necessary for its functional activity.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is upstream of the Akt pathway. GBX1 function is influenced by Akt activity; thus, by inhibiting PI3K, LY294002 reduces Akt phosphorylation and activity, which can lead to the functional inhibition of GBX1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, a protein that is involved in signaling pathways that GBX1 can be part of. By inhibiting p38 MAP kinase, SB203580 disrupts the signaling cascade that could be necessary for GBX1's functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway that can regulate GBX1 activity. By inhibiting MEK, PD98059 indirectly prevents the activation of ERK, thus inhibiting GBX1 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathways. GBX1, which may be modulated by JNK pathway signals, would experience functional inhibition due to reduced JNK activity when SP600125 is applied. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. Since GBX1 activity can be affected by PI3K/Akt signaling, inhibition of PI3K by Wortmannin would lead to decreased Akt activity and subsequently inhibit GBX1 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key protein in the PI3K/Akt pathway. Inhibition of mTOR by Rapamycin would disrupt the downstream signaling necessary for GBX1 function, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases which are upstream regulators of multiple signaling pathways that can impact GBX1 activity. By inhibiting Src kinases, PP2 can indirectly inhibit the functional activity of GBX1. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β receptor type I. The TGF-β signaling pathway is known to influence GBX1 activity, thus inhibition of this receptor can lead to functional inhibition of GBX1 by disrupting its signaling environment. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of ROCK kinase, which plays a role in actin cytoskeleton dynamics that GBX1 might interact with. Inhibition of ROCK by Y-27632 could lead to changes in cellular structure that inhibit GBX1 function. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is a selective FGFR inhibitor. FGFR signaling can interact with pathways that regulate GBX1 activity, and thus inhibition of FGFR by PD173074 would result in functional inhibition of GBX1. | ||||||